

**NIGERIA – Inactivated Polio Vaccine Support**  
This Decision Letter sets out the Programme Terms of a Programme.

<b>1. Country:</b> Nigeria				
<b>2. Grant number:</b> 1418-NGA-25b-X				
<b>3. Date of Decision Letter:</b> 22 April 2016				
<b>4. Date of the Partnership Framework Agreement:</b> 9 January 2014				
<b>5. Programme title:</b> NVS, IPV routine				
<b>6. Vaccine type:</b> Inactivated Polio Vaccine (IPV)				
<b>7. Requested product presentation and formulation of vaccine<sup>1</sup>:</b> Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID				
<b>8. Programme duration<sup>2</sup>:</b> 2015 - 2018				
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>				
	2014-2015	2016	2017	Total <sup>3</sup>
Programme Budget (US\$)	US\$14,022,889	US\$7,954,000	US\$7,983,500	US\$29,960,389
<b>10. Vaccine introduction grant:</b> Already disbursed.				
<b>11. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable)				
	Type of supplies to be purchased with Gavi funds in each year	2016		
	Number of IPV vaccines doses	8,191,600		
	Number of AD syringes	9,335,100		
	Number of safety boxes	102,700		
	Annual Amounts (US\$)	US\$7,954,000		
<b>12. Procurement agency:</b> UNICEF				
<b>13. Self-procurement:</b> Not applicable				


<sup>1</sup> Please refer to section 18 for additional information on IPV presentation.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for 2015 to 2017.

<p><b>14. Co-financing obligations:</b> Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Nigeria is encouraged to contribute to vaccine and/or supply costs for IPV.</p>							
<p><b>15. Operational support for campaigns:</b> Not applicable</p>							
<p><b>16. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>May 2016</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>		Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2016	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates						
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2016						
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat						
<p><b>17. Financial clarifications:</b> Country shall provide the following clarifications to Gavi*: Not applicable.</p> <p><i>*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements</i></p>							
<p><b>18. Other conditions:</b></p> <p>If Nigeria envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Nigeria.</p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is likely to be highly constrained at least until the end of 2017 and is unlikely to meet all country requirements during this period. As a consequence, the actual number of doses shipped may be less than the amounts specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>							

**On behalf of Gavi**



Hind Khatib-Othman  
Managing Director, Country Programmes  
22 April 2016